Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 163

1.

Is fidaxomicin the drug of choice for treating Clostridium difficile-associated diarrhea in patients with cancer?

Green MR, Acharya UH, Yeager AM.

J Clin Oncol. 2013 Dec 1;31(34):4376-8. doi: 10.1200/JCO.2013.52.8513. Epub 2013 Oct 28. No abstract available.

PMID:
24166524
2.

Reply to M.R. Green et al.

Cornely OA, Miller MA, Fantin BR, Mullane KM, Kean Y, Gorbach SL.

J Clin Oncol. 2013 Dec 1;31(34):4379. doi: 10.1200/JCO.2013.52.9420. Epub 2013 Oct 28. No abstract available.

PMID:
24166523
3.

Resolution of Clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin.

Cornely OA, Miller MA, Fantin B, Mullane K, Kean Y, Gorbach S.

J Clin Oncol. 2013 Jul 1;31(19):2493-9. doi: 10.1200/JCO.2012.45.5899. Epub 2013 May 28.

PMID:
23715579
4.

Fidaxomicin approved for C. difficile infections.

Traynor K.

Am J Health Syst Pharm. 2011 Jul 15;68(14):1276. doi: 10.2146/news110046. No abstract available.

PMID:
21719581
5.

Fidaxomicin "chaser" regimen following vancomycin for patients with multiple Clostridium difficile recurrences.

Johnson S, Gerding DN.

Clin Infect Dis. 2013 Jan;56(2):309-10. doi: 10.1093/cid/cis833. Epub 2012 Sep 28. No abstract available.

PMID:
23024296
6.

[Antimicrobial therapy of Clostridium difficile infection. Systematic review and meta-analysis of the scientific evidence].

Brodszky V, Gulácsi L, Ludwig E, Prinz G, Banai J, Reményi P, Strbák B, Kertész A, Kopcsóné Németh I, Zsoldiné Urbán E, Baji P, Péntek M.

Orv Hetil. 2013 Jun 9;154(23):890-9. doi: 10.1556/OH.2013.29627. Review. Hungarian.

PMID:
23728312
7.

Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial.

Cornely OA, Crook DW, Esposito R, Poirier A, Somero MS, Weiss K, Sears P, Gorbach S; OPT-80-004 Clinical Study Group..

Lancet Infect Dis. 2012 Apr;12(4):281-9. doi: 10.1016/S1473-3099(11)70374-7. Epub 2012 Feb 8.

PMID:
22321770
8.

Fidaxomicin versus conventional antimicrobial therapy in 59 recipients of solid organ and hematopoietic stem cell transplantation with Clostridium difficile-associated diarrhea.

Clutter DS, Dubrovskaya Y, Merl MY, Teperman L, Press R, Safdar A.

Antimicrob Agents Chemother. 2013 Sep;57(9):4501-5. doi: 10.1128/AAC.01120-13. Epub 2013 Jul 8.

9.

Sustained clinical response as an endpoint in treatment trials of Clostridium difficile-associated diarrhea.

Johnson S, Gerding DN, Louie TJ, Ruiz NM, Gorbach SL.

Antimicrob Agents Chemother. 2012 Aug;56(8):4043-5. doi: 10.1128/AAC.00605-12. Epub 2012 May 21. No abstract available.

10.

Progress with a difficult infection.

Wilcox MH.

Lancet Infect Dis. 2012 Apr;12(4):256-7. doi: 10.1016/S1473-3099(12)70013-0. Epub 2012 Feb 8. No abstract available.

PMID:
22321771
11.

Fidaxomicin versus vancomycin for Clostridium difficile infection.

Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach S, Sears P, Shue YK; OPT-80-003 Clinical Study Group..

N Engl J Med. 2011 Feb 3;364(5):422-31. doi: 10.1056/NEJMoa0910812.

12.

Clostridium difficile infection in older adults: a review and update on its management.

Kee VR.

Am J Geriatr Pharmacother. 2012 Feb;10(1):14-24. doi: 10.1016/j.amjopharm.2011.12.004. Epub 2012 Jan 20. Review.

PMID:
22260856
13.

Advances in the treatment of Clostridium difficile with fidaxomicin: a narrow spectrum antibiotic.

Sears P, Ichikawa Y, Ruiz N, Gorbach S.

Ann N Y Acad Sci. 2013 Jul;1291:33-41. doi: 10.1111/nyas.12135. Epub 2013 May 14. Review.

PMID:
23672600
14.

Fidaxomicin: a new macrocyclic, RNA polymerase-inhibiting antibiotic for the treatment of Clostridium difficile infections.

Poxton IR.

Future Microbiol. 2010 Apr;5(4):539-48. doi: 10.2217/fmb.10.20. Review.

PMID:
20353295
15.

Reduction in Clostridium difficile environmental contamination by hospitalized patients treated with fidaxomicin.

Biswas JS, Patel A, Otter JA, Wade P, Newsholme W, van Kleef E, Goldenberg SD.

J Hosp Infect. 2015 Jul;90(3):267-70. doi: 10.1016/j.jhin.2015.01.015. Epub 2015 Feb 9.

16.

Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison.

Cornely OA, Nathwani D, Ivanescu C, Odufowora-Sita O, Retsa P, Odeyemi IA.

J Antimicrob Chemother. 2014 Nov;69(11):2892-900. doi: 10.1093/jac/dku261. Epub 2014 Jul 28. Review.

PMID:
25074856
17.

[Clostridium difficile toxin-associated diarrhea in geriatrics].

Hager K, Ruwe A.

Z Gerontol Geriatr. 1998 Feb;31(1):16-21. German.

PMID:
9553219
18.

Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections.

Lancaster JW, Matthews SJ.

Clin Ther. 2012 Jan;34(1):1-13. doi: 10.1016/j.clinthera.2011.12.003. Review.

PMID:
22284993
19.

Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection.

Goldstein EJ, Citron DM, Sears P, Babakhani F, Sambol SP, Gerding DN.

Antimicrob Agents Chemother. 2011 Nov;55(11):5194-9. doi: 10.1128/AAC.00625-11. Epub 2011 Aug 15.

20.

Antibiotic treatment for Clostridium difficile-associated diarrhea in adults.

Nelson R.

Cochrane Database Syst Rev. 2007 Jul 18;(3):CD004610. Review. Update in: Cochrane Database Syst Rev. 2011;(9):CD004610.

PMID:
17636768

Supplemental Content

Support Center